trending Market Intelligence /marketintelligence/en/news-insights/trending/qF_GeVOpvAF_5YPoEFosUQ2 content esgSubNav
In This List

China approves 1st domestic HPV vaccine

Blog

Insight Weekly: Layoffs swell; energy efficiency PE deals defy downturn; 2023 global risk themes

Blog

Insight Weekly: Energy crisis cripples Europe; i-bank incomes rise; US holiday sales outlook

Blog

Japan M&A By the Numbers: Q3 2022

Blog

Insight Weekly: Reviving nuclear power; 2023 outlook for US financials; PE funds fuel EV sector


China approves 1st domestic HPV vaccine

Chinese regulators approved the country's first domestic human papillomavirus vaccine, according to a notice by the National Medical Products Administration.

The vaccine, Cecolin, is developed by private company Xiamen Innovax Biotech Co. Ltd. and Xiamen University, both based in southeast China's Fujian province.

Human papillomavirus, or HPV, is a group of more than 200 viruses among which about a dozen can cause cancers including vaginal cancer and cervical cancer.

Cecolin is now approved to help prevent females aged between 9 and 45 years old from infections with HPV types 16 and 18. The two viruses cause about 70% of cervical cancers, according to the National Cancer Institute.

There are three HPV vaccines available worldwide — GlaxoSmithKline PLC's Cervarix and Merck & Co. Inc.'s Gardasil 4 and Gardasil 9. Cervarix targets the same two viruses as Cecolin, while Gardasil 4 can prevent infection with four viruses and Gardasil 9 with nine.

Xiamen Innovax also has an HPV vaccine that targets nine viruses. That vaccine is under phase 2 study, according to the company's website.

Xiamen Innovax, established in 2005, also developed the hepatitis E vaccine Hecolin.